Fundz

R3 Vascular raises $87M in Series B financing led by Deerfield Management

PRIVATEMay 09, 2024

Amount Raised

$87 Million

Round Type

Series B

Mountain ViewManufacturingBiotechnology

Investors

415 CapitalDeerfield Management

Description

R3 Vascular closed an $87 million Series B financing round and appointed Christopher Owens as president and CEO. The company plans to use the funds to support its ELITE FDA investigational device exemption (IDE) trial for the Magnitude scaffold and to support additional R&D, global regulatory submissions, manufacturing scale-up, and initial commercialization efforts.

Quick answer

R3 Vascular raised $87 Million in a Series B round, dated May 9, 2024. Investors: 415 Capital and Deerfield Management. R3 Vascular is based in Mountain View, California, United States.

How much did R3 Vascular raise?
R3 Vascular raised $87 Million in a Series B round on May 9, 2024.
Who invested in R3 Vascular?
415 Capital and Deerfield Management are named as investors in this round.
What does R3 Vascular do?
R3 Vascular is a privately-held medical device company that develops a novel technology platform for the next generation of fully bioresorbable drug eluting sirolimus coated vascular scaffolds.
Where is R3 Vascular based and how big is it?
R3 Vascular is based in Mountain View, California, United States.
Who are the decision-makers at R3 Vascular?
Fundz holds 2 contacts at R3 Vascular. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Manufacturing and Biotechnology around the same time

Companies in the same sectors as R3 Vascular that raised within 45 days of this round, from Fundz verified event records.

  • Maxterial raised $8M (Series A) on June 20, 2024.
  • Ronovo Surgical raised $44M (Series B) on June 20, 2024.
  • Distil raised $3.1M (Funding Round) on June 20, 2024.
  • Liquid Instruments raised $15M (Private Equity) on June 19, 2024.
  • iGii raised $11M (Funding Round) on June 18, 2024.
  • Novabay raised $226K on June 14, 2024.

Who to call at R3 Vascular, and when

A new round usually means R3 Vascular is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day R3 Vascular raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at R3 Vascular, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at R3 Vascular. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

R3 Vascular

Location

Mountain View, California, United States

About

R3 Vascular is a privately-held medical device company that develops a novel technology platform for the next generation of fully bioresorbable drug eluting sirolimus coated vascular scaffolds. These are designed to deliver the ‘stent-like’ support of a scaffold along with the anti-inflammatory and anti-proliferative result of sirolimus, but ‘disappearing’ over time as the vessel heals.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment R3 Vascular raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Predictive Intelligence
Strategic

ML-powered predictions for R3 Vascular's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

R3 Vascular raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.